{"anticipatedPostingDate":"2026-06","classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.5","value":"-18.01"},{"groupId":"OG001","spread":"21.33","value":"-20.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"End of treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.47","value":"-3.52"},{"groupId":"OG001","spread":"16.59","value":"-4.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"84"}],"units":"Participants"}],"title":"3 months from end of treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.41","value":"2.70"},{"groupId":"OG001","spread":"16.15","value":"0.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"title":"6 months from end of treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.45","value":"5.37"},{"groupId":"OG001","spread":"13.81","value":"2.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"title":"12 months from end of treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"119"}],"units":"Participants"}],"description":"The EQ-5D-3L VAS measures a patient's self-rated current health state using a visual analogue scale measured on a 20-cm scale with 10-point intervals. Scores range from 0 at the bottom of the scale, representing the worst imaginable health state, to 100 at the top of the scale, representing the best imaginable health state. The change score was calculated as the postbaseline value minus the baseline value. A negative change reflects decline at the postbaseline timepoint and a positive change reflects improvement at the postbaseline timepoint.","dispersionType":"Standard Error","groups":[{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin\n\nCisplatin: 100 mg/m2 IV on days 1 and 22 of IMRT\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG000","title":"IMRT + Cisplatin"},{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab\n\nCetuximab: 400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG001","title":"IMRT + Cetuximab"}],"paramType":"MEAN","populationDescription":"Eligible participants enrolled to the quality of life (QOL) substudy who received protocol treatment and had outcome measure data at baseline and at least one postbaseline timepoint.","reportingStatus":"POSTED","timeFrame":"Basline, end of treatment (6-7 weeks), and 3, 6, and 12 months from end of treatment.","title":"EuroQol Five Dimension Scale 3-level Version (EQ-5D-3L) Visual Analogue Scale (VAS) Change From Baseline","type":"SECONDARY","unitOfMeasure":"score on a scale"}